As the global biopharma industry accelerates toward precision medicine, lipid-based nanocarriers have become critical enablers of targeted and controllable drug delivery. Among the next-generation biotech companies reshaping this space, Litchlab is gaining prominence with its integrated smart liposome platform that bridges design, targeting, controlled release, and clinical translation—addressing key challenges in cancer, gene therapy, and immunotherapy.
While established players like Evonik, Acuitas Therapeutics, and Polymun Scientific have long dominated the lipid nanoparticle (LNP) and liposome markets, Litchlab distinguishes itself through a modular platform combining targeting ligands, microenvironment-triggered release, and versatile payload compatibility, all seamlessly integrated from formulation to GMP-scale production.
Inspired by the 2025 Science Advances study demonstrating the enhanced tumor penetration of RGD-modified PEGylated liposomes, Litchlab developed a multi-responsive, targeted liposomal platform designed to optimize pharmacokinetics, drug bioavailability, and therapeutic selectivity.
Its platform features:
Ligand-targeting modules for selective tissue accumulation
Microenvironment-responsive release mechanisms for spatial-temporal control
Multi-modal payload loading across small molecules, biologics, nucleic acids, and radiopharmaceuticals
Litchlab engineers a broad portfolio of targeting moieties, including:
Peptides: RGD, NGR for angiogenesis targeting
Aptamers/Antibody fragments: HER2, EGFR, PD-L1 for tumor-specific antigens
Glycan ligands: for liver (ASGPR) or lung-specific delivery
Conjugation strategies such as EDC/NHS coupling, Click Chemistry, and Maleimide-Thiol ensure high binding efficiency and stability. In preclinical models, these targeted liposomes demonstrate 5–10× greater tumor accumulation compared to non-targeted systems.
To reduce systemic toxicity and boost efficacy, Litchlab incorporates multiple smart-release mechanisms:
| Trigger Type | Stimulus | Clinical Advantage |
|---|---|---|
| pH-sensitive | Acidic tumor microenvironment (pH 5.5–6.5) | Site-specific release, low off-target toxicity |
| GSH-sensitive | High intracellular glutathione | Selective intracellular release in tumor cells |
| Enzyme-sensitive | MMP-2/9 overexpression in tumors | Deep-tissue penetration with conditional release |
These systems significantly enhance therapeutic index and are suitable for oncological and inflammatory disease models.
Litchlab’s liposomal technology supports efficient encapsulation and delivery of:
Paclitaxel, Doxorubicin, Cisplatin
Encapsulation efficiency >85%, particle size 80–150 nm, PDI < 0.2
siRNA (e.g., KRAS, PCSK9), mRNA, CRISPR components
Preserves biological activity, suitable for liver, lung, or intramuscular delivery
Monoclonal antibodies, interferons, proteolytic enzymes
Reduced immunogenicity and extended half-life via liposomal encapsulation
Lutetium-177 (Lu-177), Zirconium-89 (Zr-89)
Enables dual-use in PET imaging and radiotherapy with RGD-targeting
Litchlab’s platform supports multiple manufacturing techniques, including thin-film dispersion, reverse-phase evaporation, and microfluidics, with scalability up to full cGMP production.
Unlike traditional CDMOs, Litchlab offers a comprehensive bench-to-clinic service model, including:
QbD-based formulation development and process optimization
ICH Q8/Q11-aligned CMC documentation for global regulatory pathways
End-to-end clinical translation support, from early-stage development to cGMP manufacturing and tech transfer
Proven track record supporting IND filings in China (NMPA), US (FDA), and Europe (EMA)
| Indication | Drug Type | Target | Delivery Platform |
|---|---|---|---|
| Breast/Ovarian Cancer | Paclitaxel/Doxorubicin | HER2 / EGFR | Targeted Liposomes |
| Liver/Pancreatic Cancer | Radiotherapeutics | αvβ3 / PD-L1 | RGD-Liposomes |
| Respiratory Vaccines | mRNA + Adhesion Proteins | TLR agonists | LNP Systems |
| Gene Silencing | siRNA (e.g., PCSK9, KRAS) | ASGPR / Integrin | siRNA-Liposomes |
In the emerging landscape of targeted therapeutics, Litchlab is pioneering a new paradigm that fuses rational design with real-world translatability. By building a robust and adaptable liposome delivery platform, Litchlab is empowering biopharma innovators worldwide to turn complex therapies into clinical reality—faster, smarter, and with greater precision.
